Atlas Trials

A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)

Clinical trial NCT01292473 · COMPLETED

Trial details

NCT number
NCT01292473
Sponsor
Genentech, Inc.
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Chronic Idiopathic Urticaria
Start date
2011-03-01
Primary completion
2012-06-01
Enrollment
323

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.